Lexicon Pharmaceuticals (LXRX) announced that the Lexicon Board of Directors has appointed Mike Exton, Ph.D. as CEO and director of Lexicon. Dr. Exton succeeds Lonnel Coats who, as previously announced, retired effective July 7, 2024. Dr. Exton most recently served as the global cardiometabolic therapeutic head at Novartis (NVS). Concurrent with Dr. Exton’s appointment as CEO, Jeff Wade has been named president and COO. Mr. Wade has served as Lexicon’s president and CFO since October 2021, having previously served in a series of finance, corporate development, administrative and legal leadership positions since joining the company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXRX:
- Lexicon resubmits sotagliflozin NDA for Type 1 Diabetes
- Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
- Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association
- Lexicon reports paper on Phase 2 RELIEF-DPN-1 trial published
- Lexicon announces publication on cost-effectiveness of INPEFA